Form 4: Amicus Therapeutics CAO Receives Equity Grant

Amicus Therapeutics' Chief Accounting Officer, Samantha Prout, was granted 32,193 Restricted Stock Units.

Summary

• Samantha Prout, Chief Accounting Officer of AMICUS THERAPEUTICS, INC. (FOLD), acquired 32,193 shares of Common Stock.
• The acquisition occurred on December 1, 2025, at a price of $0 per share.
• These shares were granted in the form of Restricted Stock Units (RSUs).
• The RSUs will vest 50% on the first anniversary of the grant date and 50% on the second anniversary of the grant date.
• Upon vesting, the RSUs will be payable in common stock, with one RSU equivalent to one share of Amicus common stock.
• Following this transaction, Samantha Prout beneficially owns 141,634 shares of common stock.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. An RSU grant to a key executive is a standard practice that aligns management's interests with shareholders, indicating a commitment to retention and long-term performance. It does not, however, provide new operational or financial performance data.

Positives

• The grant of Restricted Stock Units to a key executive like the Chief Accounting Officer aligns management's interests with those of shareholders, as the value of the compensation is tied to the company's stock performance.
• Increased insider ownership can signal confidence in the company's future prospects.

Future Outlook

The RSU grant with a two-year vesting schedule indicates a commitment to retaining key management and incentivizing long-term performance, aligning the executive's future financial interests with the company's stock performance.

Industry Context

Equity grants, particularly Restricted Stock Units, are a standard component of executive compensation packages across the biotechnology and pharmaceutical industries. They are used to attract, retain, and motivate key personnel by linking their compensation to the company's long-term success and shareholder value creation.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) as a form of equity compensation is a common practice in the biotechnology sector, comparable to compensation structures at companies like BioMarin Pharmaceutical Inc. or Sarepta Therapeutics, Inc., which frequently utilize RSUs to incentivize executives.
• The vesting schedule of 50% on the first anniversary and 50% on the second anniversary is a typical multi-year vesting approach, designed to encourage executive retention and sustained performance, similar to plans observed at peer companies.

Stakeholder Impact

• Shareholders: Increased alignment of executive interests with shareholder value creation through equity ownership.
• Employees (specifically the reporting person): Provides long-term incentive and compensation tied to company performance, potentially enhancing retention.

Next Steps

• The granted Restricted Stock Units will vest 50% on December 1, 2026.
• The remaining 50% of the Restricted Stock Units will vest on December 1, 2027.
• Upon vesting, the RSUs will be converted into shares of Amicus common stock.

Key Dates

Keywords

Amicus Therapeutics, FOLD, Samantha Prout, Chief Accounting Officer, Restricted Stock Units, RSU grant, insider transaction, equity compensation, beneficial ownership